Jardiance Vs. Farxiga

Navigating the complex landscape of type 2 diabetes treatments can often be overwhelming for patients and healthcare professionals alike. Medical researchers are continuously developing innovative solutions and refined strategies to manage and reduce the effects of diabetes. Oral medications are central to this ongoing evolution in medicine, and they have come to the forefront as pivotal tools for management of diabetes.

Among these, Jardiance® and Farxiga® stand out, consistently drawing attention within both the medical community and patient circles. These drugs, classified under the umbrella of SGLT2 inhibitors, represent progress in diabetes care, offering a unique mode of action distinct from traditional antidiabetic agents. Jardiance® is formulated with empagliflozin, while Farxiga® contains dapagliflozin.

Both Jardiance® and Farxiga® serve the same overarching objective: the regulation of blood sugar levels in people with type 2 diabetes. Yet, as with all medical treatments, it’s important to look deeper and understand the differences and shared characteristics between these drugs. While they share a common classification, each drug brings its distinctive formulation and variation in effects, underscoring the importance of informed decision-making when choosing medication.

Let’s explore the specific characteristics of Jardiance® and Farxiga®, identify their core ingredients, learn how they were developed, and compare their mechanisms of action. Through this comparison, we will better understand the efficacy of these drugs, their place in diabetes management, and the potential benefits they have beyond blood sugar regulation.

What is Empagliflozin?

Empagliflozin functions as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, purposefully designed to address high blood sugar linked to type 2 diabetes.

Origin of Empagliflozin

Empagliflozin emerged from research that aimed to find enhanced and safer diabetes treatments. The strategy involved targeting SGLT2 to decrease elevated blood sugar by enabling increased glucose excretion through the urine. A molecule was designed to inhibit the protein regulating glucose transport in the kidneys, and this molecule was empagliflozin

Empagliflozin's Mechanism of Action

By targeting SGLT2 in the kidneys, which plays a pivotal role in glucose reabsorption, empagliflozin obstructs glucose transport and leads to excess glucose expulsion through urine and stabilized blood sugar levels. Besides glucose regulation, empagliflozin aids in calorie loss due to glucose excretion, potentially contributing to slight weight reduction. This medication can also reduce the amount of insulin needed for glucose metabolism without directly influencing insulin levels.

As for dapagliflozin, its function and purpose mirror that of empagliflozin, therefore deserving equal attention in diabetes management. Dapagliflozin, like its counterpart empagliflozin, plays an instrumental role in the management of type 2 diabetes.

What is Dapagliflozin?

Dapagliflozin operates in the same category of drugs, the SGLT2 inhibitors, as empagliflozin. Its development was driven by the urgent need to manage high blood sugar levels seen in people with type 2 diabetes.

Origin of Dapagliflozin

The path to discovery of dapagliflozin paralleled that of empagliflozin and was rooted in the urgency to develop better type 2 diabetes treatments. The formulation of dapagliflozin came from precise drug design and rigorous preclinical evaluations. Researchers sought a compound that could specifically disrupt the action of the SGLT2 protein and block the transport of glucose from the kidneys back into the circulatory system. This mission led to

Dapagliflozin's Mechanism of Action

Dapagliflozin mirrors empagliflozin in how it works. It focuses on the predominance of SGLT2 in the proximal tubules of the kidneys, given the role of SGLT2 in glucose reabsorption. This makes SGLT2 a potent target for therapeutic interventions.
The medicinal effects of dapagliflozin align closely with empagliflozin and include:
  • Limiting glucose reabsorption by inhibiting SGLT2, leading to glucose being expelled through urine
    rather than returning to the bloodstream.
  • Enhancing urinary glucose removal, known as glucosuria.
  • Caloric reduction due to urinary glucose excretion, which may promote weight loss.
  • Diminishing the body’s insulin demands by cutting down blood sugar concentrations.
Both Jardiance® (empagliflozin) and Farxiga® (dapagliflozin) stand out in the therapeutic landscape due to their ability to regulate blood sugar by modulating glucose reabsorption in the kidneys. Plus, their benefits are not confined to glycemic control alone. Research trials have indicated that both drugs might have additional cardiovascular and renal advantages, further supporting their position as breakthroughs in addressing type 2 diabetes and its associated complica

Recommended Applications of Jardiance®

Jardiance® is endorsed for two primary applications:

Regulation of Diabetes

Jardiance® is predominantly recommended for adults for regulation of type 2 diabetes. Its mechanism allows greater control over glycemic levels by reducing elevated blood sugar levels.

Mitigation of Cardiovascular Risks

Jardiance® plays a pivotal role in reducing the chances of critical cardiovascular complications, such as heart attacks and cerebral strokes, in people with type 2 diabetes. It also reduces the likelihood of progression of cardiovascular issues or associated incidents. Jardiance® promotes these benefits through:
  • Glucose Regulation via SGLT2: This process amplifies glucose excretion via urine, thereby curbing high
    blood sugar concentrations.
  • Optimization of Blood Pressure: Clinical observations have shown that Jardiance® helps regulate blood pressure among type 2 diabetes patients. Stabilized blood pressure reduces the burden on the cardiac system and reduces risk of cardiovascular events.
  • Promotion of Weight Reduction: Administration of Jardiance® can result in a slight weight loss among people with type 2 diabetes. Shedding weight improves cardiovascular wellness by rectifying issues linked to insulin
    reactivity and lipid metrics.
  • Safeguarding against Heart Ailments: Jardiance® has received accolades for reducing hospital admissions due to heart malfunction in adults with cardiac issues characterized by diminished ejection fraction.
  • Anti-Inflammatory Potency: Preliminary research suggests that SGLT2 suppressors, like Jardiance®, could provide anti-inflammatory benefits to the cardiac system, potentially improving positive cardiovascular outcomes.

Recommended Applications of Farxiga®

Farxiga® has been endorsed for various clinical uses, including:

Diabetes Control

Farxiga® is recommended for the control of type 2 diabetes in adults. It can be administered as a standalone medication or in combination with other diabetes treatments.

Heart Health Maintenance

Farxiga® (dapagliflozin) is used to decrease the likelihood of heart failure hospitalizations in adults diagnosed with type 2 diabetes and recognized cardiovascular issues. It does this through several vital pathways:
  • SGLT2 Blockade: This action diminishes glucose reuptake in kidney structures. The excess glucose is then expelled through urine, leading to a decrease in blood glucose. This reduces the cardiovascular pressure induced by
    elevated blood sugar.
  • Fluid Reduction: The blockade of SGLT2 by Farxiga® also results in greater elimination of sodium and fluids through urine. This fluid reduction effect is instrumental in blood pressure reduction. A subsequent drop in blood pressure alleviates heart burden and minimizes the chances of heart failure or exacerbation of present cardiac conditions.
  • Body Weight Reduction: Farxiga® has the potential to cause slight weight reduction in those with type 2 diabetes. Often, weight reduction sets the stage for enhanced cardiovascular health due to reduced heart load.
  • Heart and Kidney Advantages: Farxiga® demonstrates heart and kidney advantages, including the minimization of risk of hospitalizations due to cardiovascular mortality and heart failure, as well as delay of the onset of kidney issues linked with diabetes.
  • Anti-inflammatory Capabilities: Similar to Jardiance®, research indicates that Farxiga® possesses cardiovascular anti-inflammatory properties, which might be linked to better heart health outcomes.

Administration and Dosage Guidelines

Both Jardiance® and Farxiga® come in pill form and are meant for oral consumption.

Jardiance® Dosage Instructions

The suggested initial dose for Jardiance® is 10 mg daily. If there’s a need for further blood sugar regulation, the dose can be raised to 25 mg daily.

Farxiga® Dosage Instructions

Typically, Farxiga® is administered at a dose of 5 mg daily. If greater blood sugar management is required, the dosage can be enhanced to 10 mg daily. The 10 mg dosage is also preferred for people diagnosed with cardiovascular ailments or for those having type 2 diabetes accompanied by several cardiovascular risk elements.

Potential Adverse Reactions

Both Jardiance® and Farxiga® fall under the same drug category, leading to some overlapping side effects. However, each medication has its specific side effects as well.
  • Yeast infections in the genital area

  • Infections in the urinary tract

  • Elevated urine output

  • Excessive thirst

  • Reduced blood pressure

Both Jardiance® and Farxiga® fall under the same drug category, leading to some overlapping side effects. However, each medication has its specific side effects as well.

Distinct Adverse Reaction for Jardiance®: Frequent urination
Distinct Adverse Reactions for Farxiga®: Inflammation affecting the nasal passage and throat, discomfort in the back region and skin disturbances (rashes, itchiness).


The landscape of type 2 diabetes treatments is continually evolving, and among the pivotal tools in diabetes management are oral medications like Jardiance® and Farxiga®. These SGLT2 inhibitors play a crucial role in regulating blood sugar levels in people with type 2 diabetes. While both medications share a common classification, they have distinct formulations and mechanisms of action.

Jardiance®, with empagliflozin as its primary ingredient, targets glucose reabsorption in the kidneys, leading to increased glucose excretion through urine, stabilized blood sugar levels, and potential weight reduction. It also offers cardiovascular and renal benefits.

Jardiance® (Empagliflozin):
  • Efficiently regulates blood sugar concentrations in those with type 2 diabetes.
  • Showcases exceptional benefits related to cardiovascular health, reducing the likelihood of severe cardiovascular events, including but not limited to myocardial infarctions and cerebrovascular incidents. These effects are attributed to mechanisms such as SGLT2 obstruction, systemic blood pressure moderation, weight reduction, and mitigation of inflammatory responses.
  • Decreases hospital admissions due to heart failure among adults with diminished ejection fraction, enhancing its applicability for patients with known cardiovascular ailments.
  • Might play a role in stalling the progression of kidney disorders in people diagnosed with type 2 diabetes.

Farxiga®, containing dapagliflozin, operates similarly, reducing blood sugar and offering cardiovascular advantages, including lowering the risk of heart failure hospitalizations.

Farxiga® (Dapagliflozin):
  • Controls blood sugar levels in adults diagnosed with type 2 diabetes, as a standalone
    treatment or combined with other glucose-lowering agents.
  • Reduces the odds of hospital stays stemming from heart failure in patients with type 2 diabetes and verified cardiovascular issues through mechanisms such as SGLT2 blockade, diuretic impacts, weight reduction, and benefits to the heart and kidneys, along with possible anti-inflammatory properties.
  • Improves symptoms and enhances recovery in patients with heart failure.

Both Jardiance® and Farxiga® are taken orally and exhibit shared adverse reactions like genital fungal infections, urinary infections, augmented urination, dehydration, and hypotension. Jardiance® is associated with more frequent urination, while Farxiga® might induce symptoms like upper respiratory tract inflammation, dorsalgia, and dermal reactions.

These medications represent significant strides in managing type 2 diabetes, not only in glycemic control but also in potential ancillary benefits for the cardiovascular system. It’s essential for people managing type 2 diabetes to work closely with their healthcare providers to determine the most appropriate treatment plan tailored to their specific needs and goals.

Potential Adverse Reactions

Product was successfully added to your cart!